Capricor Therapeutics Inc (CAPR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Capricor Therapeutics Inc (CAPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8282
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced heart failure and duchenne muscular dystrophy associated cardiomyopathy. Its lead candidate CAP- 1002 is an allogeneic cardiosphere-derived cell product which is in phase II clinical stage for the treatment of adult cardiology indications. Capricor offers research programs on cell therapy, natriuretic peptides and exosome platforms. It also conducts clinical trials for the development of novel therapeutics to prevent and treat cardiac and other serious medical conditions. Capricor is headquartered in Beverly Hills, California, the US.

Capricor Therapeutics Inc (CAPR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Capricor Therapeutics Acquires Intellectual Property Rights to Natriuretic Peptides from Medtronic 11
Venture Financing 12
Capricor Therapeutics Raises Funds through Venture Financing 12
Partnerships 13
Capricor Therapeutics Enters into Agreement with US Army Institute of Surgical Research 13
Licensing Agreements 14
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 14
Equity Offering 16
Capricor Therapeutics Files Registration Statement to Raise up to USD14 Million in Public Offering of Shares 16
Capricor Therapeutics Plans to Raise up to USD1 Million in Public Offering of Shares 17
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 18
Capricor Therapeutics Raises USD11 Million in Public Offering of Shares 19
Capricor Therapeutics to Raise USD4 Million in Private Placement of Shares and Warrants 21
Capricor Therapeutics to Raise USD7 Million in Private Placement of Shares 22
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 23
Debt Offering 25
Capricor Therapeutics Raises USD0.4 Million in Private Placement of Note 25
Capricor Therapeutics Inc – Key Competitors 26
Capricor Therapeutics Inc – Key Employees 27
Capricor Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 09, 2018: Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update 29
May 10, 2018: Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 31
Mar 14, 2018: Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update 33
Nov 08, 2017: Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program 35
Aug 10, 2017: Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 36
May 15, 2017: Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 37
Mar 15, 2017: Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 38
Corporate Communications 39
Dec 20, 2017: Capricor Therapeutics: Departure of Directors or Certain Officers; Election of Directors 39
Other Significant Developments 40
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Capricor Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Capricor Therapeutics Acquires Intellectual Property Rights to Natriuretic Peptides from Medtronic 11
Capricor Therapeutics Raises Funds through Venture Financing 12
Capricor Therapeutics Enters into Agreement with US Army Institute of Surgical Research 13
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 14
Capricor Therapeutics Files Registration Statement to Raise up to USD14 Million in Public Offering of Shares 16
Capricor Therapeutics Plans to Raise up to USD1 Million in Public Offering of Shares 17
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 18
Capricor Therapeutics Raises USD11 Million in Public Offering of Shares 19
Capricor Therapeutics to Raise USD4 Million in Private Placement of Shares and Warrants 21
Capricor Therapeutics to Raise USD7 Million in Private Placement of Shares 22
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 23
Capricor Therapeutics Raises USD0.4 Million in Private Placement of Note 25
Capricor Therapeutics Inc, Key Competitors 26
Capricor Therapeutics Inc, Key Employees 27

List of Figures
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Capricor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Capricor Therapeutics Inc (CAPR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vestas Wind Systems AS (VWS):企業の財務・戦略的SWOT分析
    Vestas Wind Systems AS (VWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Geisinger Health System-製薬・医療分野:企業M&A・提携分析
    Summary Geisinger Health System (GHS) is an integrated health services organization that provides medical and surgical specialties and sub-specialties, and related health services. It offers a range of medical services for patients suffering from diseases related to cardiology, ENT, gastroenterology …
  • Vaccibody AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vaccibody AS (Vaccibody) is a vaccine company that provides discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines. The company develops VB10.16, a DNA based immunotherapy targeting malignancies caused by human papilloma virus. It conducts exploratory safet …
  • Barco N.V.:企業の戦略・SWOT・財務情報
    Barco N.V. - Strategy, SWOT and Corporate Finance Report Summary Barco N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Definiens AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Definiens AG (Definiens), a subsidiary of AstraZeneca Plc, is a healthcare technology company that offers image analysis and data mining solutions. The company offers products such as tissue studio, developer, image miner, server, architect and viewer, among others. Its services include cons …
  • The Sherwin-Williams Company:企業の戦略・SWOT・財務分析
    The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report Summary The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • EDP – Energias do Brasil SA:企業の戦略・SWOT・財務情報
    EDP - Energias do Brasil SA - Strategy, SWOT and Corporate Finance Report Summary EDP - Energias do Brasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sherwin-Williams Co (SHW):企業の財務・戦略的SWOT分析
    Sherwin-Williams Co (SHW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Gilead Sciences, Inc.:企業のM&A・事業提携・投資動向
    Gilead Sciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gilead Sciences, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • TOA OIL Co Ltd (5008):企業の財務・戦略的SWOT分析
    Summary TOA OIL Co Ltd (TOA OIL), a subsidiary of Showa Shell Sekiyu KK is an oil and gas company that offers contract refining of crude oil. The company offers products such as diesel oil, coker naphtha scrubber, kerosene, polynaphtha units, LPG hydrofining unit, gasoline scrubber, and vacuum diese …
  • Electric Power Development Co Ltd:発電所・企業SWOT分析
    Electric Power Development Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Gard P & I (Bermuda) Ltd.
    Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mondi Limited:企業の戦略・SWOT・財務情報
    Mondi Limited - Strategy, SWOT and Corporate Finance Report Summary Mondi Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • AMETEK Inc (AME):企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturer. The company manufactures electronic instruments and electromechanical devices. Its product portfolio includes medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys a …
  • CoreSite Realty Corp (COR):企業の財務・戦略的SWOT分析
    CoreSite Realty Corp (COR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Telefonica UK Limited:企業の戦略的SWOT分析
    Telefonica UK Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Abcam Plc (ABC):製薬・医療:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • TeleTech Holdings, Inc. (TTEC):企業の財務・戦略的SWOT分析
    TeleTech Holdings, Inc. (TTEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Cherkizovo Group OJSC (GCHE):企業の財務・戦略的SWOT分析
    Cherkizovo Group OJSC (GCHE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • TechnoPhage SA:製薬・医療:M&Aディール及び事業提携情報
    Summary TechnoPhage SA (TechnoPhage) is a biopharmaceutical company that offers contract research and development of new molecules. The company conducts its research and development of new products based on unique properties of bacteriophages. It also conducts contract research and development servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆